生物灵感的心脏向金属有机框架纳米酶用于调节心力衰竭中的炎症反应,并保留了喷射分数
Yuesheng Gui1,2, Xiaowan Fan3, Kairui Xiao2
1Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Frontiers in bioengineering and biotechnology
|March 2, 2026
概括
一种针对心脏的新型纳米酶,NanoAM,通过减少氧化应激和改善胰岛素耐药性,有效地治疗保留喷射分数 (HFpEF) 的实验性心力衰竭. 这种仿生方法为HFpEF提供了一个有前途的新治疗策略.
科学领域:
- 生物材料科学 生物材料科学
- 心血管研究研究心血管研究
- 纳米医学是一种纳米医学.
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭是一种普遍的疾病,治疗选择有限.
- 炎症和氧化应激是HFpEF病理生理学的关键因素.
- 现有的抗氧化剂疗法已经显示出不足的疗效.
研究的目的:
- 开发和评估一种新的针对心脏的纳米酶,用于HFpEF治疗.
- 研究纳米酶的治疗机制,包括ROS清理和信号通路的调制.
主要方法:
- 一种生物模拟的配ZIF-8纳米酶 (MnZIF) 的合成,用心脏 natriuretic (ANP) 修改,以创建NanoAM.
- 在由高脂肪饮食和L-NAME诱导的小鼠HFpEF模型中对NanoAM的评估.
- 评估使用心声回声学,压力-体积循环分析,组织学,转录学和体外研究.
主要成果:
- 纳米AM显示出强大的SOD/CAT模仿活性,心脏向性和生物相容性.
- 在HFpEF小鼠中,NanoAM显著改善了心脏功能,降低了血压,改善了心脏重塑.
- 通过SOCS3-IRS1-AKT2-GLUT4路径,NanoAM有效地清除了活性氧物种 (ROS),减少了炎症,并增强了胰岛素敏感性.
结论:
- 一种针对心脏的新型纳米酶,NanoAM,在实验模型中有效缓解HFpEF病理.
- 纳米AM通过双重机制发挥治疗作用:ROS清理和改善胰岛素信号传递.
- 多功能纳米酶代表了对复杂的心血管疾病 (如HFpEF) 的有前途的治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:30Heart Failure V: Medical Management
429
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
429
01:29Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:14Myocarditis III: Medical Management
266
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266